amezalpat
amezalpat: sourced relationships with 1 company · 2 clinical trials tracked.
amezalpat evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could amezalpat → TPST affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Tempest Therapeutics, Inc. (TPST) first-line unresectable or metastatic hepatocellular carcino… | Phase 3 |
Clinical Trial Registry Records (2)
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of TPST-1120 in Combination With Atezolizumab Plus Bevacizumab Compared With Placebo Plus Atezolizumab Plus Bevacizumab in Patients With Unresectable or Metastatic Hepatocellular Carcinoma (HCC) Not Previously Treated With Systemic Therapy
Primary endpoint: Overall Survival (OS)
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)
Primary endpoint: Objective Response Rate (ORR)
Frequently asked questions
Which companies have sourced relationships with amezalpat?
amezalpat has dated SEC/FDA relationship records for Tempest Therapeutics, Inc..
How many clinical trials involve amezalpat?
BioSniper tracks 2 clinical trials involving amezalpat.